We examined the genetic basis for adenosine deaminase (ADA) deficiency in seven patients with late/delayed onset of immunodeficiency, an underdiagnosed and relatively unstudied condition. Deoxyadenosine-mediated metabolic abnormalities were less severe than in the usual, early-onset disorder. Six patients were compound heterozygotes; 7 of 10 mutations
Introduction
In 80-90% of cases, deficiency of adenosine deaminase (ADA)' results in severe combined immunodeficiency disease (SCID) (1) (2) (3) . Failure to thrive and life-threatening opportunistic infections begin in infancy and are associated with profound lymphopenia and absence of cellular and humoral immune function. Marked accumulation of dATP and loss of S-adenosylhomocysteine hydrolase (SAHase) activity in erythrocytes of these patients are specific consequences of impaired deoxyadenosine (dAdo) catabolism (4) (5) (6) (7) . In contrast to this dramatic and often fatal syndrome, about a dozen healthy children with normal immune function have been identified through population screening for erythrocyte ADA deficiency. They differ from SCID patients in having substantial residual ADA activity in nucleated cells (so-called "partial" ADA deficiency), minimal elevation in erythrocyte dATP, and a different spectrum ofADA gene mutations (reviewed in references 3 and 8) . Nearly all ofthe ADA mutations reported to date have been from these two groups.
Two other phenotypes with intermediate severity have been recognized. In one, onset of serious infections is "delayed," beginning by about 6-12 mo of age. Humoral immunity may be less severely affected and infections, at least initially, less serious than in typical SCID patients; diagnosis is usually made by the age of 2-3 yr. The fourth group has a later clinical onset, few opportunistic infections, and gradual clinical and immunological deterioration. "Late" and "delayed" onset are somewhat arbitrary designations since age at onset may be difficult to pinpoint and patients with similar immunologic and clinical characteristics may be diagnosed at different ages depending on the experience of treating physicians. Nevertheless, it is estimated that 10-15% ofADA deficient patients have delayed onset (1) (2) (3) . To date only four patients diagnosed beyond the age of 4 yr have been reported (9, 10; Weinberg et al., manuscript in preparation). Because of their atypical features (and because ADA deficiency in any form is rare), lateonset patients are probably underdiagnosed. Indeed, some may be among patients with so-called "HIV-negative CD4 T lymphopenia with immunodeficiency of unknown etiology" (Weinberg et al., manuscript in preparation ).
We have examined ADA gene mutations of four late-and three delayed-onset patients who are among a clinically diverse group (now > 40) who have been treated with polyethylene glycol-modified bovine ADA (PEG-ADA) during the past -7 yr (3, 11, 12) . This report is part of a long-term study of this relatively large patient population, aimed at better defining the relationship of genotype to metabolic abnormality, clinical severity, and response to restoration ofADA activity (by enzyme replacement or gene therapy).
Methods
T cells were cultured from peripheral blood mononuclear cells as described (13) except that culture medium contained 15% heat-inactivated (30 min, 56°) fetal bovine serum (GIBCO, Laboratories, Grand Island, NY) and 50 U/ml IL-2 (Boehringer Mannheim Biochemicals, Indianapolis, IN) instead of T cell-conditioned medium.
Analysis ofADA gene mutations. Standard procedures were used for subcloning and restriction enzyme analysis (14) and for PCR (15, 16) ; recommendations ofthe suppliers ofreagents used in these procedures were followed. Genomic DNA (17) and total cellular RNA (18) were prepared as described. First-strand cDNA was synthesized from 5 ug oftotal cellular RNA using a first-strand cDNA synthesis kit (Pharmacia Inc., Piscataway, NJ). PCR primers for ADA cDNA and genomic DNA are given in Table I . Wild-type ADA cDNA and genomic sequences are as reported (19, 20) . ADA cDNA sequences are numbered relative to the start oftranslation and genomic DNA according to Wiginton et al. (20) .
Reverse transcriptase-PCR was used to amplify a "full-length" ADA cDNA fragment extending from 61 bp 5' of the translation start codon to 311 bp 3' ofthe stop codon. In some cases a smaller fragment containing only the ADA coding region (bp 1-1091) was amplified. The PCR product was precipitated with isopropanol, treated with EcoRI and HindIII (IBI, New Haven, CT), purified on QIAEX (QIA-GEN, Chatsworth, CA), and then subcloned into pUC18. Doublestranded DNA was sequenced with [35S]dATP (Amersham Corp., Arlington Heights, IL) using Sequenase (U.S. Biochemical, Cleveland). After gel purification, uncloned genomic DNA PCR products were sequenced using the cycle sequencing kit (Bethesda Research Laboratories, Rockville, MD) with 32P-end-labeled sequencing primers. For each patient, a minimum of six cDNA subclones containing the full coding region were sequenced to identify candidate mutations. For confirmation, PCR-amplified segments of genomic DNA were then analyzed by sequencing and where possible, restriction enzyme digestion, as described in Results. 2 In vitro expression. "Full-length" mutant ADA cDNA subclones (after sequencing the entire coding region to establish that only the mutation of interest was present) were recloned into pBluescript SK+ (Stratagene, Inc., La Jolla, CA) and transcribed in vitro using T7 RNA polymerase to generate sense RNA. A similarly prepared full-length PCR fragment prepared from the normal ADA cDNA clone pADA2 11 (19) was used as a wild-type control. The size and yield of transcripts were verified on agarose-formaldehyde gels. An aliquot ofthe RNA was then used to prime a rabbit reticulocyte lysate translation system in the presence of ["S]methionine (Promega Corp., Madison, WI). An aliquot (5 Ml) of the reaction was electrophoresed on cellulose acetate (Helena Labs, Beaumont, TX) and stained for ADA activity in situ, as described (13) . The size ofthe 35S-labeled translation product was analyzed by mercaptoethanol/ 10% SDS polyacrylamide gel electrophoresis and fluorography, performed after treating the gel with Enhance (Dupont Co., Wilmington, DE). In experiments where immunoreactivity of the translation product was analyzed, aliquots of translation reactions were incubated at 4°C overnight in a volume of 0.5 ml containing 2 Ml of goat anti-human ADA antibody (provided by Drs.
2. Sequencing gels documenting single-base changes in exons and previously reported mutations, which were provided for review, are not presented as figures in order to save Journal space. The authors will make the primary data available to interested readers. $ After amplification (see reference 61), the 1022-bp product, spanning intron 9 to intron 11, was digested with PstI to yield a 849-bp fragment containing exons 10 and I1 and the intervening intron; this was subcloned into the PstI site of pUC 18 prior to sequencing.
2292
Bruce Aronow and Dan Wiginton), or with nonimmune goat serum.
The samples were then incubated for 2 h with 50 ,l ofa 10% suspension of fixed staphylococcus A (Pansorbin, Calbiochem Corp., San Diego, CA), and then centrifuged for 5 min in a microcentrifuge. The staph pellets were washed three times with NET-gel buffer (14) and then analyzed by SDS gel electrophoresis as above.
Results

Patients
Late onset. Patients AlNe, AnRo, AA (9, 21, 22) , and CC (10, 12) were relatively asymptomatic until 2-5 yr of age, when recurrent respiratory problems, including sinusitis, bronchitis, asthma, and pneumonia became prominent features. By the time ADA deficiency was discovered at 5-15 yr of age (Table  II) , chronic pulmonary insufficiency was present to varying degree in AA, AlNe, and AnRo. At diagnosis all were T lymphopenic (Table II) ; in vitro response of lymphocytes to mitogens was diminished and response to antigens was absent. Immunoglobulin levels and specific antibody responses to prior infection and immunization were variable. However, relatively well-preserved T cell function and humoral immunity had been documented 3 yr before diagnosis in patients AlNe and AnRo (Weinberg et al., in preparation). Dysregulation of immunity and hematopoiesis were also present. AA had autoimmune thyroid insufficiency, CC had eosinophilia and a deficiency of the IgG2 subclass, and IgE was elevated in both CC and AlNe. At diagnosis AlNe was pancytopenic and transient pancytopenia and a hypocellular marrow were found in AnRo 3 yr before diagnosis; the relationship to ADA deficiency is unclear.
Delayed onset. JH was diagnosed at the age of 14 mo when she presented with Pneumocystis carinii pneumonia and recurrent diarrhea from about 9 mo of age (23) . AD was diagnosed at the age of 2 yr during evaluation for a persistent cough. She had been treated for pneumonia at 1 yr of age and for nasal congestion and cough since the age of 3 mo, but she had never been hospitalized ( 12 ) . AD developed transient autoimmune thrombocytopenia after a viral infection soon after diagnosis. T lymphopenia (Table II) and reduced or absent lymphocyte responses to mitogens were found at diagnosis; immunoglobulin levels were variable but titers of specific antibody were low or absent.
MJ was discovered to be ADA deficient at the age of 3 yr when she was evaluated for failure to thrive and chronic interstitial pneumonia. Lung biopsy showed extensive scarring with bronchiolitis obliterans; no etiologic agent was identified. Recurrent pulmonary infections and asthma dated from 1 yr of age. Lymphopenia (620/mm3) was present at diagnosis without significant abnormalities in distribution of lymphocyte subsets. Mitogen responses of peripheral blood lymphocytes and quantitative immunoglobulins were normal, but antibodies to tetanus and diphtheria were absent despite adequate immunization. Delayed skin test reaction to tetanus toxoid was absent, but converted to positive on ADA replacement therapy, correlating with resolution of her lymphopenia.
Except for an unsuccessful trial of deoxycytidine infusion, intended to relieve inhibition of ribonucleotide reductase by dATP (21, 22) , patient AA received no specific therapy aimed at restoring endogenous immune function until PEG-ADA was begun at the age 15 yr, 7 yr after diagnosis. The other patients began treatment with PEG-ADA at the time ofdiagnosis. All have shown sustained improvement in clinical status and immune function ( 10, 12, 24) (and Weinberg et al., manuscript in preparation). They all continue to receive PEG-ADA, including patients CC and AD, who have also received experimental treatments with ADA gene-transduced T cells sporadically during the past 2-3 yr ( 12) . MJ has required steroids and monthly immunoglobulin infusions ( 1 g/kg) to control symptoms related to chronic bronchiolitis obliterans. (Table II) . In pretreatment red cells, dAdo nucleotides (dATP in the case of JH, total deoxyadenosine nucleotides (dAXP) in the other 6) ranged from 60 to 289 nmol/ml (normal, < 2 nmol/ml). These values are intermediate between those of typical SCID patients and healthy individuals with partial ADA deficiency. Among the latter dATP is < 20 nmol/ml (reviewed in Hershfield and Mitchell [31] ), while in 12 newly diagnosed, untransfused SCID patients (samples analyzed at Duke University Medical Center), red cell dAXP ranged from -350 to > 1800 nmol/ml (Table II) .
Erythrocyte SAHase activity ranged from 6% to 24% of normal, and exceeded 10% in five of the seven late/delayed-onset subjects. Among the 12 SCID patients, SAHase was < 10% of normal in nine, and < 5% in six (Table II) . AlNe, the oldest patient at diagnosis, had the mildest red cell metabolic abnormalities.
ADA 3' splice junction (25, 26) (Fig. 1 C) . Besides introducing nine new codons after Leu325, use of the cryptic splice site shifts the reading frame to include 268 bp of the normal 3' noncoding region before a new TGA stop codon is generated 16 bp from the polyA addition signal (Fig. 1 D) . The mutant protein is predicted to consist of 463 residues with a mass of 52,275 Kd, vs. 363 residues and 40,762 Kd for the normal ADA protein. Although the normal 3' splice site in intron 10 remains, the cryptic site is used preferentially in the patient's cultured T cells. Thus, no normal sized PCR product was detectable by ethidium bromide staining when a fragment spanning exons 10 and 11 was amplified from cDNA prepared from total T cell RNA (Fig. 1 E) .
Patient AnRo. Four cDNA subclones had a G > A transition at bp 529, which changes codon 177 (exon 6) from GTG Val to ATG Met, and introduces a new NcoI site (data not shown). Two subclones lacked this change, but had a deletion ofthe AG dinucleotide at bp 1019-1020 (exon 11) (Fig. 2 A) .
Heterozygosity for these mutations was demonstrated by direct sequencing of exon 6 amplified from genomic DNA, and of amplified and subcloned genomic DNA spanning exons 10-11 (data not shown). Neither of these mutations has previously been reported. A1019-1020 shifts the mRNA reading frame, changing amino acids 340-348 from KRELLDLLY to KGASRPALX, where X348 is a new TAA translation termination signal. Variable reduction in steady-state levels of transcripts bearing premature stop codons has frequently been observed (27) (28) (29) (30) . We estimate the level ofthe A1019-1020 transcript to be 30% to > 50% of that of the Val 177 > Met transcript. We infer this because two ofsix cDNA subclones had the deletion, and because the relative intensity of bands representing the two alleles generated by NcoI digestion ofamplified cDNA was similar to that of the analogous bands generated from amplified genomic DNA (Fig. 2 B) .
Patient CC. Four amplified cDNA subclones possessed a G > T transversion at bp 302, changing Arg (CGG) to Leu (CTG) at codon 101 in exon 4 (data not shown). Four subclones lacked this change, but had a C > T transition at bp 872, which changes codon 291 from Ser (TCG) to Leu (TTG) in exon 10 (data not shown). Both mutations were confirmed by direct sequencing of amplified genomic DNA (data not shown). The Arg O1 > Leu mutation has not been reported, but Ser291 > Leu has recently been identified independently (31 Patients JH and MJ. CfoI digestion of exon 5 amplified from genomic DNA (Fig. 3, lanes 1-3) and direct sequencing (data not shown) showed that JH and MJ were each heterozygous for the Argl 56 > His mutation found in patient AA. However, CfoI digestion of uncloned amplified cDNA prepared from T cells (MJ) or fibroblasts (JH) gave only the mutant pattern (Fig. 3, lanes 4-6) , indicating that the second ADA allele in each case was either not expressed or was expressed at a very low level. Multiple cDNA subclones were then digested to identify any with Argl 56 (wild type) as candidates for the second allele.
In the case of JH, 2 of 36 cDNA subclones had Argl56. Both had a 4-bp insertion, ATGA, after bp 974, at the exon 10-1 1 junction (Fig. 4A) . Direct sequencing ofamplified genomic DNA revealed heterozygosity for a G > A transition at bp + 1 of intron 10, changing the wild-type splice donor sequence from gtgagt to atgagt (Fig. 4 B) JH fibroblasts use of a cryptic splice donor at bp +5 of intron 10 (gtgggt) results in inclusion of the first four intronic bp (including the mutation) in mRNA. As a result, amino acids 326-334 at the start of exon 11 are changed from the wild-type NINAAKSSF to MKHQCGQIX. The new TAG stop signal at codon 334, which eliminates 30 carboxy-terminal residues, apparently accounts for the very low abundance of the corresponding mRNA.
In the case of MJ, 1 of 28 cDNA subclones analyzed lacked the mutation at codon 156. Sequencing revealed a deletion in exon 10 of GAAGA, bp 955-959 from the start of translation (data not shown). Heterozygosity for this 5-bp deletion was demonstrated by sequencing subclones of amplified exon 10 genomic DNA, and by showing heterozygosity for a new BpmI site in the uncloned genomic PCR product (data not shown). This deletion shifts the reading frame and mutates codons 319-321 from EEE to GVX, eliminating the last 43 amino acids. This same 5-bp deletion has recently been found in a patient with early-onset SCID3 and in unrelated ADA-deficient patients (36) . MJ lacks a polymorphism, Lys8O > Arg, found in one of these patients, suggesting an independent origin, consistent with the suggestion that the mutation is at a deletional hot spot. 3 Patient AD. BstXI digestion ofexon 7 amplified from genomic DNA showed that AD was heterozygous for the Gly216 > Arg mutation (data not shown). Of20 cDNA subclones analyzed, 17 were mutant and 3 wild type at codon 216. The latter in each case lacked exon 5, with precise joining of exon 4 to exon 6 (Fig. 5 A) . Complete sequencing of one full-length cDNA clone missing exon 5 revealed no other mutations. These findings suggested a mutation that affected splicing of exon 5. Direct sequencing ofamplified genomic DNA revealed wild-type exon 4/intron 4, intron 4/exon 5, and intron 5/exon 6 junctions, and there were no changes in exon 5. However, at bp +6 of intron 5 both A and the normal T were present (gtgagt/a). The intron 5 T"6 > A transversion was subsequently found in 5 of 10 subclones derived from the amplified genomic segment (Fig. 5 B) .
Loss ofexon 5 shifts the ADA mRNA reading frame, changing the amino acid sequence after codon 121 and creating a TAA stop signal at codon 131. To estimate the abundance of mRNA lacking exon 5, a segment spanning exons 2-6 was amplified from cDNA prepared from AD T cells and analyzed on an agarose gel. The normal-sized product was obtained, but no band ofthe size expected for deletion ofexon 5 was detected by ethidium bromide staining, indicating very low abundance (data not shown). ADA activity ofmutant proteins expressed in vitro In vitro translation ofRNA transcribed from cDNA, combined with in situ assay for ADA activity, was used to determine whether the putative mutations identified were capable of causing ADA deficiency. Equal amounts of mutant and wildtype translation products were compared in the in situ assay. In the experiment shown in Fig. 6 1020, ArglO 1 > Leu, Ser29 1 > Leu, and Argl 56 > His cDNAs were tested. The major band generated from the wild-type transcript and from mRNAs with amino acid substitutions migrated just ahead ofthe ovalbumin (46 kD) marker (Fig. 6 A) . acetate (Fig. 6 B) . Of the mutants tested, only the Argl56 > His product (lane 8) showed detectable ADA activity, and this was much fainter than for the wild-type translation product; this result was reproducible. In other experiments not presented, no activity was detected with the Gly216 > Arg in vitro translation product, consistent with transient expression studies in cos cells (32) . The translation product derived from the intron 10 G+' > A splice donor mutation (JH), which is truncated at codon 334, was of the expected size and was also inactive (data not shown). The major translation product derived from AlNe cDNA, which is predicted to have 100 more amino acid residues than wild type ADA, had an estimated mass of 57-58 kD (Fig. 7 A) . Although this is larger than the 52 kD expected, the wild-type translation product was also larger than expected on this gel, 46 kD instead of 41 Both the mutant and wild-type 35S-labeled peptides were specifically precipitated with antibody to human ADA (Fig. 7 B) . ADA activity of the mutant translation product was undetectable (Fig. 7 C, left panel) . However, sufficient activity was present in extracts of AlNe T cells to detect by in situ assay. The activity, presumably derived from mRNA generated by use of the cryptic 3' splice site, migrated more slowly than wild-type ADA (Fig. 7 C, right panel) .
Further characterization ofthis "macro-ADA" will be reported elsewhere.
Discussion
Among the seven patients studied, all 14 chromosomes were accounted for and 10 different mutations were identified. These included two short deletions and five missense mutations located in exons 4, 5, 6, 7, 10, and 1; and three splicing defects in introns 5 and 10 (Table III) . One of the deletions, three of the amino acid substitutions, and the three splicing defects are novel. In vitro translation products bearing the new mutations lacked or had much less enzymatic activity than an equivalent amount of wild-type translation product, evidence that the mutations cause ADA deficiency. Further studies of expression of cloned cDNAs in intact cells and of purified, overexpressed enzymes will be needed to assess the stability and kinetic properties ofthe mutant proteins, and their contribution to residual cellular ADA function.
Environmental There is evidence that the capacity to eliminate dAdo is related to disease severity. Specifically, the degree of dAXP pool expansion and SAHase inactivation in erythrocytes reflect exposure to circulating dAdo (red cells lack dAdo precursors), and hence total residual ADA function (discussed in Hershfield and Mitchell [ 3 ] ). Abnormalities in these parameters in the late/delayed-onset patients under study were less marked than in typical SCID patients, but more severe than in individuals with partial ADA deficiency (see Results), consistent with the working hypothesis. An important corollary ofthis hypothesis is that, in conferring a mild phenotype, an allele that provides some functional ADA will be dominant to one that eliminates function. This simplifies evaluation of the contribution ofindividual mutations to disease severity in compound heterozygotes, i.e., six of the seven patients studied.
The Argl 56 > His mutation found in patients AA, MJ, and JH, had detectable in situ ADA activity. It is very unlikely that the second alleles of these patients are functional. The 5-bp deletion in the case of MJ, and the invariant G+' splice donor mutation in the case of JH, resulted in proteins predicted to be truncated by 43 and 30 carboxy-terminal amino acids, respectively, and in each case very low levels of the corresponding mRNA were detected. The second mutation in late onset patient AA (and also in delayed onset patient AD) is Gly216 > Arg. Homozygosity for this mutation was found in a single patient with a very severe phenotype (32) . Our experience with other patients, to be presented elsewhere, confirms that Gly2 16 > Arg, when it is the only expressed allele, is associated with severe metabolic abnormalities and early-onset SCID. It is noteworthy that the Argl 56 > His mutation occurs at a CpG mutational hot spot (37, 38) . The fact that it has been found in three patients with delayed or late onset and none with the more common SCID presentation further supports the conclusion that it confers a relatively mild phenotype. Although Argl 56 > His has not previously been reported, substitution ofCys for Argl 56 has been found in a SCID patient who responded transiently to partial exchange transfusion (31) . Response to the relatively low level ofADA activity provided by this'treatment was considered unusual and an indication of relatively mild disease.
Either of the alleles possessed by CC, ArglOl > Leu and Ser291 > Leu, could contribute to her mild metabolic and clinical phenotype. Ser29 1 > Leu has been identified independently in an ADA-deficient SCID patient, who showed improvement during red cell transfusion therapy (31) . ArglOl > Leu has not yet been found in other patients, but ArglO 1 > Gln was apparently the only allele expressed in a patient with mild disease (39) (40) (41) . ArglOl > Trp was found in a SCID patient whose second mutation was Arg2 11 > His (42). Cultured T cells from this patient were found to express significant levels of ADA activity, though it was unclear which allele was responsible for this activity ( 13 ) .
Neither Val 177 > Met nor Ai1019-1020 found in late onset patient AnRo have previously been described; either one, or the combination, could provide sufficient enzymatic activity to diminish disease severity. A1019-1020 in exon 11 changes seven of eight amino acids after codon 341 and terminates translation at codon 348, eliminating the last 16 residues. However, abundance ofthe mRNA for this allele was not as severely reduced as with the frame shifting alleles of patients AD, MJ, and JH, which generate premature stop signals at codons 131, 321, and 334, respectively. This is consistent with polarity effects of premature stop signals on mRNA stability for other genes (28) (29) (30) 43) . No point mutations responsible for ADA deficiency have been reported beyond Ala 329. Moreover, wild-type murine ADA, which otherwise is highly homologous, is 11 amino acids shorter than human ADA, and the "missing" residues are all at the carboxy terminus (44) . Based on the crystal structure of murine ADA (45) , the carboxy terminal residues affected by A 10 19-1020 should be located far from the active site.
It is noteworthy that M1019-1020 lies within 60 bp of A955-959 found in MJ. Each occurs in a segment that contains multiple short direct repeats, a motifthat appears to predispose to short deletions, and each is part ofa sequence that resembles a consensus short deletional hot spot, TGA/GA/GG/TA/C (46). Thus, as has been noted,3 the A955-959 segment, TTTAGTgaagaGGAGTTTA (deleted bases in lower case), has three GA and a TTTA repeat (underlined) . Similarly, the A1019-1020 segment, AGAAGATGAAAggGGAG, has four AG repeats and is part of an AAG repeat. If M1019-1020 is a hot spot, it will be interesting to see whether it occurs selectively in patients with late or delayed onset rather than early onset SCID.
AlNe is homozygous for a G > A mutation at bp -34 from the intron 10/1I1 junction. The cryptic splice acceptor activated by this mutation was highly favored over the normal site in his cultured T cells. A number oflocal and long-range "context" factors govern selection among alternative splice sites (47, 48) . In the present case, the cryptic splice site has five A residues located 22-33 bp 5' of the new splice junction that might be used as a branchpoint; the wild-type splice acceptor for intron 10 has only two, at -16 and -28 bp (Fig. 1C) . Use of the cryptic splice site results in an enzyme 100 amino acids longer than normal. Preliminary studies (A. Mary and M. S. Hershfield, unpublished observation) suggest that the mutant enzyme accounts for the residual ADA activity detected in T cells of the patient. Whether it accounts entirely for his quite mild metabolic abnormality and remarkable survival to the age of 15 yr before diagnosis remains to be determined. A low level of normal enzyme may be generated by use of the normal splice site in some cell types. In this regard, tissue and patientspecific variation in splicing efficiency appear to account for the variable phenotype associated with an unusual splicing mutation in the HexB gene (49) . Differences in nuclear processing ofpre-mRNA have been postulated to play a role in regulating ADA levels in certain cell lines (50), though whether or not splicing is involved is unclear.
In the case ofAD, skipping ofexon 5 results from the splice donor mutation T6 > A in intron 5. Skipping of a preceding exon due to splice donor site mutations has been observed in patients with several other genetic disorders (51) (52) (53) (54) (55) (56) (57) . This finding may be explained by the "exon definition" model (58) , in which the splicing machinery first binds at a 3' splice acceptor site, then searches downstream for a 5' splice site; definition of the exon is then followed by rearrangement ofthe splicing components to allow intron removal. In this model, if a splice acceptor site is not followed within 300 bp by a proper 5' splice donor site the exon is deleted or a cryptic splice donor site in the exon may be used, as in the case ofa bp +6 mutation in IVS 1 of the f3-globin gene (59, 60) . Inspection of ADA exon 5 shows a potential, though nonconsensus splice donor site, AGgtggtg, at bp 21-28 from the 5' end, which apparently is not used in the cells of patient AD.
Skipping ofexon 5 markedly destabilizes the corresponding mRNA and results in a protein truncated at codon 131, which is undoubtedly inactive. As discussed above, AD's second mutation, Gly2 16 > Arg is unlikely to contribute to her mild phenotype. It is possible that factors other than ADA genotype are involved. However, as discussed for AlNe, it is possible that correct splicing at exon 5 occurs in some cell type(s), providing sufficient dAdo catabolizing activity to ameliorate disease. In this regard the +6 mutation in ,B-globin allowed some normal processing to occur and resulted in a mild ,B+ thalassemia phenotype (59) . Further studies of the role of tissue specific splicing in determining phenotype in patients such as AD and AlNe are planned.
